Skip to Main Content
August 13, 2020

Health Law Daily

Researchers Say Clinical Trials For Gilead’s Remdesivir In COVID-19 Lacked Equal Representation For Diverse Groups

  • August 13, 2020

FierceBiotech (8/12, Taylor) reports, “Researchers have called for sponsors of COVID-19 clinical trials to run more diverse studies” after “an analysis of Gilead’s remdesivir clinical trials that found the studies ‘failed to provide equal representation of Black, Latinx and Native Americans.’” The analysis was published in the New England Journal of Medicine.